Back
Sep 30
Education

EDU 49 - Evolving Role of Consolidative Radiation Therapy for Gastrointestinal Malignancies

Room 310-312
04:00pm - 05:00pm PT
Gastrointestinal Cancer

MODERATOR(S)

Suzanne Mary Russo, MD - Case Western Reserve School of Medicine

session DESCRIPTION

A subset of patients with limited metastatic cancer coined oligometastatic disease can benefit from aggressive local therapy, such as SABR, thus prolong survival by eradicating all sites of visible cancer. Initial single-arm reports of patients treated with this approach showed impressive results and have led to the development of randomized trials aiming to demonstrate improved survival with the addition of SAbR to standard-of-care systemic therapy. (1, DaPalma). The variety of biology and presentations of oligometastatic GI cancers makes it difficult to conduct randomized controlled trials. Radiation therapy is a treatment option for oligometastatic gastrointestinal (GI) cancers, and it can help improve locoregional control and progression-free survival. We will discuss current treatment guidelines and paradigms for GI oligometastatic disease in a multidisciplinary case-based approach to optimize patient outcome, survival and quality of life.

learning objectives

  1. For gastrointestinal (GI) oligometastatic cancer, the objectives of reviewing ongoing research and clinical trials aim to bridge the gap in evidence regarding patient selection and treatment decisions. These efforts are particularly important for refining treatment strategies, optimizing patient outcomes, and defining the characteristics of GI oligometastatic disease more precisely.
  2. Discuss multidisciplinary approaches and treatment guidelines with biomarkers, molecular testing to optimize systemic an local therapy to improve the prognosis for patients with oligometastatic disease, moving toward an individualized, evidence-driven care paradigm.

Credits

AMA PRA Category 1 Credits: 1.00

Presentations